Result
-€102,323 -€102,323
From profit to loss in 2024, after a profit of €577,668 in 2023.
PharmaLex Belgium
Lifetime
8 annual accounts with figures on one time axisTurnoverpeak €8.4m (2024)
€8.4m▲ 19.7%
Resultlowest -€102,323 (2024)
-€102,323▼ €679,991
Equitypeak €2.5m (2023)
€2.4m▼ 4.2%
Debts
€2.5m▼ 23.8%
Staffpeak 50 FTE (2023)
47.1 FTE▼ 5.8%
Board17 names since 2016all names
6 directorsPharmaLex France SAS and 5 others
Owners3 names in the annual accounts
100%AmerisourceBergen International B.V.
Documentsfilings and deeds
19-08-2026476 days late
2024financial year
Turnover from €7.0m to €8.4mLoss of €102,323Appointment: Deloitte Réviseurs d'Entreprises (statutory audi… 26-04Debts from €3.3m to €2.5mInvestments €366,384Cash from €1.9m to €1.1m
Key points
from the 2024 annual accountsInvestments
€426,352 2.2 × depreciation
Green is investment, beige is depreciation. Machinery stands 15.3% higher than in 2023.
Payment terms
84 days to suppliers
PharmaLex Belgium pays its suppliers 33 days earlier than in 2023. Customers pay 63 days earlier.
Filings
8 annual accounts 190 days past the deadline
2025 accounts not filed: deadline was 30-04-2026.
Board
4 joined · 4 left
Board changed. Latest change 01-10-2026 · 4 in office.
Position in the sector
-€102,323
Lower net result than 90% of companies in head offices and management consultancy. Sector median €45,251 · 4,593 companies.
2024 figures too old to score
Bankruptcy probability
No current score
Figures too old
The latest figures are for FY 2024. They are too old for a current score.
Bankruptcy probability: Elevated
Filing: One annual filing is missing
Bankruptcy probability within 12 months
6.7% Elevated
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.1% across 4,522 companies (NACE 70, small).
About 7 in 100 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.1%
01-2025: 0.1%● unchanged vs 12-2024lowest value
02-2025: 0.1%● unchanged vs 01-2025
03-2025: 0.1%● unchanged vs 02-2025
04-2025: 0.1%● unchanged vs 03-2025
05-2025: 0.2%▲ +0.1 percentage points vs 04-2025
06-2025: 0.2%● unchanged vs 05-2025
07-2025: 0.4%▲ +0.2 percentage points vs 06-2025
08-2025: 0.4%● unchanged vs 07-2025
09-2025: 0.5%▲ +0.1 percentage points vs 08-2025
10-2025: 0.6%▲ +0.1 percentage points vs 09-2025
11-2025: 0.6%● unchanged vs 10-2025
12-2025: 0.6%● unchanged vs 11-2025
01-2026: 0.6%● unchanged vs 12-2025
02-2026: 0.6%● unchanged vs 01-2026
03-2026: 0.6%● unchanged vs 02-2026
04-2026: 0.6%● unchanged vs 03-2026
05-2026: 3.6%▲ +3.0 percentage points vs 04-2026
06-2026: 3.6%● unchanged vs 05-2026
07-2026: 3.6%● unchanged vs 06-2026
08-2026: 3.9%▲ +0.3 percentage points vs 07-2026
09-2026: 5.1%▲ +1.2 percentage points vs 08-2026
10-2026: 6.7%▲ +1.6 percentage points vs 09-2026highest value
11-2026: 6.7%● unchanged vs 10-2026highest value
Financial strength, FY 2024Strong
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises risk
raises risk · Annual accounts not filed
The financial year that closed on 30-09-2025 was due at the National Bank by 30-04-2026. Nothing is on record, 190 days later.
NBB · 8 filingsPosition against the passed deadline
30-09-2025 year end30-04-2026 deadline06-11-2026 today
raises risk · 2024 accounts filed 476 days late
The financial year that closed on 30-09-2024 was due by 30-04-2025 and was filed on 19-08-2026, 476 days past the deadline. Measured on financial year 2023: of the companies more than 90 days late, 5.61% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers.
NBB · 8 filingsDeviation from the deadline
2025
not filed
2024
476 days late
2023
84 days late
2022
7 days early
2021
2 days early
2020
8 days early
2019
8 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 6 accounts on average 89 days after the deadline. In the sector (NACE 70), the median for financial year 2024 was 9 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (1)
Board and ownership
DR
Deloitte Réviseurs d'Entreprises
Auditor, Julie Delforge
- AmerisourceBergen International B.V. 100%annual accounts 30-09-2024
Recent changes
4 directors appointed, 3 resignations
Resignations: Christopher Gauglitz, Anne Peeters and PharmaLex France SAS (day-to-day manager) · Permanent representative: Åsa Pihlblad · Appointments: Åsa Pihlblad, Maria Beatriz Rosado Caeiro, Jens Hellmig and Joris de Ruysscher (day-to-day manager) · General meeting of 23-09-2026 · Gazette deed
Capital increase of €2,200,000 to €2,318,600
Capital from €118,600 to €2,318,600 · General meeting of 25-09-2026 · Gazette deed
Registered office moved from Mont-Saint-Guibert to Zaventem
New registered office: Weiveldlaan 3/5 1930 Zaventem · Previous registered office: Rue Edouard Belin 5 1435 Mont-Saint-Guibert · General meeting of 13-04-2026 · Gazette deed
Permanent representative: Åsa Pihlblad
Board meeting of 04-02-2026 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | Turnover | EBIT margin | Solvency | Staff |
|---|---|---|---|---|
| PharmaLex Belgium Zaventem | €8.4m | 1.3% | 47.4% | 47.1 |
| KPMG Deal Advisory Zaventem | €11.1m | 1.3% | 9.1% | 39.7 |
| EY SOLUTIONS Machelen (Brab.) | €13.7m | 1.5% | 30.4% | 43.7 |
| RUD PEDERSEN PUBLIC AFFAIRS BRUSSELS Brussels | €11.6m | 11.1% | 29.7% | 44 |
| JLG Ground Support Europe Genk | €12.7m | 4.0% | 76.7% | 49.5 |
| EMAC Belgium Charleroi | €7.3m | 3.6% | 10.4% | 47.3 |
| Care 4 Fleets Vilvoorde | €14.9m | 1.0% | 7.0% | 45.8 |
Grey: the largest companies of the sector (head offices and management consultancy (NACE 70)), without their names. Blue: the sector peers from the table.
These companies have the same main activity as PharmaLex Belgium: business and other management consultancy (NACE 70200). They are comparable in size and age: total assets between €3.8m and €6.5m, founded between 2009 and 2019.
Official details
Source: KBO- Status
- Active since 19-12-2016Normal situation
- Activity
- Business and other management consultancyNACE 70200and 1 other
- Joint committees
- 100Auxiliary committee for blue-collar workers
- 200Auxiliary committee for white-collar workers · annual accounts 2022
- Establishment unit
- 2.352.876.4411930 Zaventem, since 01-08-2023
- Financial year end
- 30 September
- Peppol
- Reachable since 10-12-2025
Annual accounts to 30-09-2024
- Total assets
- €5.0m▼ 15.3%
- Employeeson 30-09-2024
- 50▲ 2.0%
- Filing
- Filed on 19-08-2026
Insights on PharmaLex Belgium
PharmaLex Belgium has existed since 2016. In 2018 turnover rose from €510,000 to €1.9m.
Turnover has grown every year since. Solvency rose in 2024 from 41.9% to 47.4% because of lower debts.
AmerisourceBergen International B.V. holds all the shares. In February 2023, four directors stepped down.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about PharmaLex Belgium
- What is the company number of PharmaLex Belgium?
- The company number of PharmaLex Belgium is 0667.829.063. The VAT number is the same number with BE in front: BE 0667.829.063.
- Where is PharmaLex Belgium based?
- The registered office is at Weiveldlaan 3, 1930 Zaventem.Company details
- What does PharmaLex Belgium do?
- According to the KBO register, the main activity is business and other management consultancy (NACE 70200).
- What is the legal form of PharmaLex Belgium?
- PharmaLex Belgium is a public limited company (NV).
- When was PharmaLex Belgium founded?
- PharmaLex Belgium was founded on 19-12-2016.
- Is PharmaLex Belgium still active?
- Yes, PharmaLex Belgium is an active enterprise in the KBO register.
- How many employees does PharmaLex Belgium have?
- PharmaLex Belgium had an average of 47.1 full-time equivalents in financial year 2024, according to the filed annual accounts.Financials
- Which joint committee does PharmaLex Belgium fall under?
- In its 2022 annual accounts, PharmaLex Belgium states joint committees 100 (Auxiliary committee for blue-collar workers) and 200 (Auxiliary committee for white-collar workers).
- What is the turnover of PharmaLex Belgium?
- The turnover of PharmaLex Belgium was €8.4m in financial year 2024, according to the filed annual accounts.
- Is PharmaLex Belgium profitable?
- In financial year 2024, PharmaLex Belgium made a loss of €102,323.
- Where can I find the annual accounts of PharmaLex Belgium?
- PharmaLex Belgium filed 8 annual accounts with the National Bank of Belgium, the latest for financial year 2024.
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies Compare this company with its sector.Sector benchmark
See how customers, suppliers and banks see your own company and what to improve first.